Current Yield with Participation Funds (CYwP Funds) announced today that Current Yield with Participation Fund II (CYwP Fund II) has invested in Halo Labs, instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Founded in 2010, Halo Lab’s core mission has been to provide researchers with unprecedented insights into the particles present in their processes by leveraging our core scientific competency: novel optics.
In 2017, the company rebranded to Halo Labs and discontinued the existing instruments in order to focus on the commercialization of its new platform, the Horizon. Horizon is based on a unique membrane-based approach to particle characterization that provides a higher throughput workflow at a lower cost than traditional methods.
Today, Halo Labs dedicates its collective experience and novel technology to empower formulation researchers to learn more about the stability and quality of their biological drugs faster and with more accuracy than ever.